Decision to list interventional radiology products supplied by Teleflex Medical New Zealand Limited
We are pleased to announce the approval of a listing agreement for a range of interventional radiology products with Teleflex Medical New Zealand Limited.
In summary this will result in:
- Listing 109 Interventional Radiology products from Teleflex in Part III of Section H of the Pharmaceutical Schedule from 1 November 2018 under a national agreement that all DHBs may purchase under (“Agreement”).
- DHBs continuing to be able to purchase other suppliers’ brands of interventional radiology products.
This Agreement would supersede any existing DHB contracts with this supplier for the devices listed in the Schedule 1 of the Agreement.
Any changes to the original proposal?
This decision was subject to consultation with a letter dated 13 September 2018.
During consultation it was identified that one of the GTINs was incorrect. Schedule 1 of the Agreement was amended to correct this.
Who we think will be most interested
- DHB staff
- Interventional radiology staff
- Theatre staff
- Perioperative staff
- Procurement Officers
- Suppliers and Wholesalers
Detail about this decision
In September 2017 PHARMAC issued a Request for Proposals (“RFP”) for interventional radiology products for non-exclusive national agreements for listing on the Pharmaceutical Schedule.
After completing the RFP evaluation processes and consulting on the provisional Agreement reached with Teleflex, PHARMAC has decided to list Teleflex’s range of interventional radiology products in Part III of Section H of the Pharmaceutical Schedule from 1 November 2018.
The list of Teleflex products will be available on PHARMAC's website from 1 November 2018, in both a PDF document and an Excel spreadsheet.
DHBs that purchase Teleflex’s interventional radiology products must do so under the terms and conditions, and at the prices, included in the Agreements, from 1 November 2018. DHBs can continue to choose which interventional radiology products they purchase.
Our response to what you told us
We appreciate the time people took to respond to this consultation.
A summary of the main themes raised in feedback and our responses to the feedback received are set out below:
PHARMAC Staff Comment
Ministry of Health advising no technical resource impacts anticipated as a result of proposals
If you have any questions about this decision, you can email us at firstname.lastname@example.org; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.